ICML 2019 | Acalabrutinib in ibrutinib-intolerant CLL patients: opening new doors

Kerry Rogers

Kerry Rogers, MD, from the Ohio State University, Columbus, OH, discusses the Phase II study (NCT02717611) of acalabrutinib in ibrutinib-intolerant chronic lymphocytic leukemia (CLL) patients, and the potential implications of this data. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video